Dr. Strickler on Dosing Regorafenib in CRC

John H. Strickler, MD, medical oncologist, Duke Cancer Center, Duke Health, discusses dosing strategies with regorafenib (Stivarga) in colorectal cancer (CRC).

Findings from the phase 2 ReDOS trial showed that a dose-escalation dosing strategy with regorafenib has comparable activity and fewer adverse effects compared with standard dosing.

As such, rather than pushing for the 160-mg dose of regorafenib, dosing should be tailored based on individual patients’ tolerability, says Strickler. The goal is to offer patients maximum quality of life without compromising efficacy.

Additionally, the data from ReDOS do not suggest that patients who start at lower doses of regorafenib, such as 80 mg or 120 mg, and then gradually escalate treatment derive less benefit than those patients who begin at the full dose. As such, it is important to focus on tolerability, because higher doses of regorafenib do not necessarily confer more favorable outcomes, concludes Strickler.